Inhibition of oncostatin M in osteoarthritic synovial fluid enhances GAG production in osteoarthritic cartilage repair

European Cells and Materials

Volumn 26, Issue , 2013, Pages 80-90

  Beekhuizen, Michiel ^a   van Osch, Gerjo J V M ^b   Bot, Arjan G J ^a   Hoekstra, Myrthe C L ^a   Saris, Daniel B F ^a,c   Dhert, Wouter J A ^a,d   Creemers, Laura B ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF TWENTE   (Netherlands)

^d UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Cartilage; Oncostatin M; Osteoarthritis

Indexed keywords

GAG PROTEIN; GLYCOSAMINOGLYCAN; LEUKEMIA INHIBITORY FACTOR RECEPTOR; ONCOSTATIN M; ONCOSTATIN M RECEPTOR;

ARTICLE; ARTICULAR CARTILAGE; CARTILAGE CELL; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INHIBITION KINETICS; OSTEOARTHRITIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; SYNOVIAL FLUID; SYNOVIUM; TISSUE METABOLISM; TISSUE REPAIR;

ANTIBODIES, BLOCKING; CARTILAGE; CASE-CONTROL STUDIES; GLYCOSAMINOGLYCANS; HUMANS; ONCOSTATIN M; OSTEOARTHRITIS; SYNOVIAL FLUID;

EID: 84884689498     PISSN: 14732262     EISSN: None     Source Type: Journal    
DOI: 10.22203/eCM.v026a06     Document Type: Article

References (51)

1. Allan EH, Hilton DJ, Brown MA, Evely RS, Yumita S, Metcalf D, Gough NM, Ng KW, Nicola NA, Martin TJ (1990) Osteoblasts display receptors for and responses to leukemia-inhibitory factor. J Cell Physiol 145: 110-119.
2. Barksby HE, Hui W, Wappler I, Peters HH, Milner JM, Richards CD, Cawston TE, Rowan AD (2006) Interleukin-1 in combination with oncostatin M up-regulates multiple genes in chondrocytes: implications for cartilage destruction and repair. Arthritis Rheum 54: 540-550.
3. Beekhuizen M, Bastiaansen-Jenniskens YM, Koevoet W, Saris DB, Dhert WJ, Creemers LB, van Osch GJ (2011) Osteoarthritic synovial tissue inhibition of proteoglycan production in human osteoarthritic knee cartilage: establishment and characterization of a long-term cartilage-synovium coculture. Arthritis Rheum 63: 1918-1927.
4. Beekhuizen M, Gierman LM, van Spil WE, Van Osch GJ, Huizinga TW, Saris DB, Creemers LB, Zuurmond AM (2013) An explorative study comparing levels of soluble mediators in control and osteoarthritic synovial fluid. Osteoarthritis Cartilage 21: 918-922.
5. Catterall JB, Carrere S, Koshy PJ, Degnan BA, Shingleton WD, Brinckerhoff CE, Rutter J, Cawston TE, Rowan AD (2001) Synergistic induction of matrix metalloproteinase 1 by interleukin-1alpha and oncostatin M in human chondrocytes involves signal transducer and activator of transcription and activator protein 1 transcription factors via a novel mechanism. Arthritis Rheum 44: 2296-2310.
6. Cawston TE, Curry VA, Summers CA, Clark IM, Riley GP, Life PF, Spaull JR, Goldring MB, Koshy PJ, Rowan AD, Shingleton WD (1998) The role of oncostatin M in animal and human connective tissue collagen turnover and its localization within the rheumatoid joint. Arthritis Rheum 41: 1760-1771.
7. de Jager W, te Velthuis H, Prakken BJ, Kuis W, Rijkers GT (2003) Simultaneous detection of 15 human cytokines in a single sample of stimulated peripheral blood mononuclear cells. Clin Diagn Lab Immunol 10: 133-139.
8. de Jager W, Prakken BJ, Bijlsma JW, Kuis W, Rijkers GT (2005) Improved multiplex immunoassay performance in human plasma and synovial fluid following removal of interfering heterophilic antibodies. J Immunol Methods 300: 124-135.
9. Durigova M, Roughley PJ, Mort JS (2008a) Mechanism of proteoglycan aggregate degradation in cartilage stimulated with oncostatin M. Osteoarthritis Cartilage 16: 98-104.
10. Durigova M, Soucy P, Fushimi K, Nagase H, Mort JS, Roughley PJ (2008b) Characterization of an ADAMTS-5-mediated cleavage site in aggrecan in OSM-stimulated bovine cartilage. Osteoarthritis Cartilage 16: 1245-1252.
11. Durigova M, Troeberg L, Nagase H, Roughley PJ, Mort JS (2011) Involvement of ADAMTS5 and hyaluronidase in aggrecan degradation and release from OSM-stimulated cartilage. Eur Cell Mater 21: 31-45.
12. Farndale RW, Buttle DJ, Barrett AJ (1986) Improved quantitation and discrimination of sulphated glycosaminoglycans by use of dimethylmethylene blue. Biochim Biophys Acta 883: 173-177.
13. Fearon U, Mullan R, Markham T, Connolly M, Sullivan S, Poole AR, FitzGerald O, Bresnihan B, Veale DJ (2006) Oncostatin M induces angiogenesis and cartilage degradation in rheumatoid arthritis synovial tissue and human cartilage cocultures. Arthritis Rheum 54: 3152-3162.
14. Felson DT (2006) Clinical practice. Osteoarthritis of the knee. N Engl J Med 354: 841-848.
15. Fernandes JC, Martel-Pelletier J, Pelletier JP (2002) The role of cytokines in osteoarthritis pathophysiology. Biorheology 39: 237-246.
16. Garnero P, Thompson E, Woodworth T, Smolen JS (2010) Rapid and sustained improvement in bone and cartilage turnover markers with the anti-interleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a substudy of the multicenter double-blind, placebo-controlled trial of tocilizumab in inadequate responders to methotrexate alone. Arthritis Rheum 62: 33-43.
17. Gearing DP, Comeau MR, Friend DJ, Gimpel SD, Thut CJ, McGourty J, Brasher KK, King JA, Gillis S, Mosley B, Ziegler SF, Cosman D (1992) The IL-6 signal transducer, gp130: an oncostatin M receptor and affinity converter for the LIF receptor. Science 255: 1434-1437.
18. Gilbert SJ, Blain EJ, Al-Sabah A, Zhang Y, Duance VC, Mason DJ (2012) Protein kinase R plays a pivotal role in oncostatin M and interleukin-1 signalling in bovine articular cartilage chondrocytes. Eur Cell Mater 23: 41-57.
19. Goldring SR, Goldring MB (2004) The role of cytokines in cartilage matrix degeneration in osteoarthritis. Clin Orthop Relat Res 427 Suppl: S27-36.
20. Goldring MB, Marcu KB (2009) Cartilage homeostasis in health and rheumatic diseases. Arthritis Res Ther 11: 224.
21. Halfter H, Friedrich M, Postert C, Ringelstein EB, Stogbauer F (1999) Activation of Jak-Stat and MAPK2 pathways by oncostatin M leads to growth inhibition of human glioma cells. Mol Cell Biol Res Commun 1: 109-116.
22. Hashimoto J, Garnero P, van der Heijde D, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Yoshikawa H, Nishimoto N (2011) Humanized anti-interleukin-6-receptor antibody (tocilizumab) monotherapy is more effective in slowing radiographic progression in patients with rheumatoid arthritis at high baseline risk for structural damage evaluated with levels of biomarkers, radiography, and BMI: data from the SAMURAI study. Mod Rheumatol 21: 10-15.
23. Hui W, Bell M, Carroll G (1997) Detection of oncostatin M in synovial fluid from patients with rheumatoid arthritis. Ann Rheum Dis 56: 184-187.
24. Hui W, Rowan AD, Cawston T (2000) Transforming growth factor beta1 blocks the release of collagen fragments from boving nasal cartilage stimulated by oncostatin M in combination with IL-1alpha. Cytokine 12: 765-769.
25. Hui W, Rowan AD, Cawston T (2001) Insulin-like growth factor 1 blocks collagen release and down regulates matrix metalloproteinase-1,-3,-8, and-13 mRNA expression in bovine nasal cartilage stimulated with oncostatin M in combination with interleukin 1alpha. Ann Rheum Dis 60: 254-261.
26. Hui W, Rowan AD, Richards CD, Cawston TE (2003) Oncostatin M in combination with tumor necrosis factor alpha induces cartilage damage and matrix metalloproteinase expression in vitro and in vivo. Arthritis Rheum 48: 3404-3418.
27. Hui W, Cawston TE, Richards CD, Rowan AD (2005) A model of inflammatory arthritis highlights a role for oncostatin M in pro-inflammatory cytokine-induced bone destruction via RANK/RANKL. Arthritis Res Ther 7: R57-64.
28. Maini RN, Taylor PC, Szechinski J, Pavelka K, Broll J, Balint G, Emery P, Raemen F, Petersen J, Smolen J, Thomson D, Kishimoto T (2006) Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 54: 2817-2829.
29. Manicourt DH, Poilvache P, Van Egeren A, Devogelaer JP, Lenz ME, Thonar EJ (2000) Synovial fluid levels of tumor necrosis factor alpha and oncostatin M correlate with levels of markers of the degradation of crosslinked collagen and cartilage aggrecan in rheumatoid arthritis but not in osteoarthritis. Arthritis Rheum 43: 281-288.
30. Martel-Pelletier J, Alaaeddine N, Pelletier JP (1999) Cytokines and their role in the pathophysiology of osteoarthritis. Front Biosci 4: D694-703.
31. Martel-Pelletier J, Boileau C, Pelletier JP, Roughley PJ (2008) Cartilage in normal and osteoarthritis conditions. Best Pract Res Clin Rheumatol 22: 351-384.
32. Mastbergen SC, Bijlsma JW, Lafeber FP (2005) Selective COX-2 inhibition is favorable to human early and late-stage osteoarthritic cartilage: a human in vitro study. Osteoarthritis Cartilage 13: 519-526.
33. Miyajima A, Kinoshita T, Tanaka M, Kamiya A, Mukouyama Y, Hara T (2000) Role of oncostatin M in hematopoiesis and liver development. Cytokine Growth Factor Rev 11: 177-183.
34. Mosley B, De Imus C, Friend D, Boiani N, Thoma B, Park LS, Cosman D (1996) Dual oncostatin M (OSM) receptors. Cloning and characterization of an alternative signaling subunit conferring OSM-specific receptor activation. J Biol Chem 271: 32635-32643.
35. Nishimoto N, Hashimoto J, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Murata N, van der Heijde D, Kishimoto T (2007) Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis 66: 1162-1167.
36. Nowell MA, Richards PJ, Fielding CA, Ognjanovic S, Topley N, Williams AS, Bryant-Greenwood G, Jones SA (2006) Regulation of pre-B cell colony-enhancing factor by STAT-3-dependent interleukin-6 trans-signaling: implications in the pathogenesis of rheumatoid arthritis. Arthritis Rheum 54: 2084-2095.
37. Okamoto H, Yamamura M, Morita Y, Harada S, Makino H, Ota Z (1997) The synovial expression and serum levels of interleukin-6, interleukin-11, leukemia inhibitory factor, and oncostatin M in rheumatoid arthritis. Arthritis Rheum 40: 1096-1105.
38. Plater-Zyberk C, Buckton J, Thompson S, Spaull J, Zanders E, Papworth J, Life PF (2001) Amelioration of arthritis in two murine models using antibodies to oncostatin M. Arthritis Rheum 44: 2697-2702.
39. Pritzker KP, Gay S, Jimenez SA, Ostergaard K, Pelletier JP, Revell PA, Salter D, van den Berg WB (2006) Osteoarthritis cartilage histopathology: grading and staging. Osteoarthritis Cartilage 14: 13-29.
40. Rosenberg L (1971) Chemical basis for the histological use of safranin O in the study of articular cartilage. J Bone Joint Surg Am 53: 69-82.
41. Rowan AD, Koshy PJ, Shingleton WD, Degnan BA, Heath JK, Vernallis AB, Spaull JR, Life PF, Hudson K, Cawston TE (2001) Synergistic effects of glycoprotein 130 binding cytokines in combination with interleukin-1 on cartilage collagen breakdown. Arthritis Rheum 44: 1620-1632.
42. Royuela M, Ricote M, Parsons MS, Garcia-Tunon I, Paniagua R, de Miguel MP (2004) Immunohistochemical analysis of the IL-6 family of cytokines and their receptors in benign, hyperplasic, and malignant human prostate. J Pathol 202: 41-49.
43. Rutgers M, Saris DBF, Auw Yang KG, Dhert WJA, Creemers LB (2009) Joint injury and osteoarthritis: soluble mediators in the course and treatment of cartilage pathology. Immunotherapy 1: 435-445.
44. Sims NA, Walsh NC (2010) GP130 cytokines and bone remodelling in health and disease. BMB Rep 43: 513-523.
45. Tanaka T, Umesaki N (2003) Oncostatin M inhibits decidualization of normal human endometrial stromal cells. Int J Mol Med 11: 627-630.
46. Tanaka M, Hirabayashi Y, Sekiguchi T, Inoue T, Katsuki M, Miyajima A (2003) Targeted disruption of oncostatin M receptor results in altered hematopoiesis. Blood 102: 3154-3162.
47. Thoma B, Bird TA, Friend DJ, Gearing DP, Dower SK (1994) Oncostatin M and leukemia inhibitory factor trigger overlapping and different signals through partially shared receptor complexes. J Biol Chem 269: 6215-6222.
48. van Diest PJ (2002) No consent should be needed for using leftover body material for scientific purposes. For. BMJ 325: 648-651.
49. Vignon E, Balblanc JC, Mathieu P, Louisot P, Richard M (1993) Metalloprotease activity, phospholipase A2 activity and cytokine concentration in osteoarthritis synovial fluids. Osteoarthritis Cartilage 1: 115-120.
50. Walker EC, McGregor NE, Poulton IJ, Solano M, Pompolo S, Fernandes TJ, Constable MJ, Nicholson GC, Zhang JG, Nicola NA, Gillespie MT, Martin TJ, Sims NA (2010) Oncostatin M promotes bone formation independently of resorption when signaling through leukemia inhibitory factor receptor in mice. J Clin Invest 120: 582-592.
51. Znoyko I, Sohara N, Spicer SS, Trojanowska M, Reuben A (2005) Expression of oncostatin M and its receptors in normal and cirrhotic human liver. J Hepatol 43: 893-900.